Aaron Weitzman / Axios:
Boston-based PhaseV, which is developing AI software to accelerate clinical trials and drug development, raised a $50M Series A co-led by Accel and Insight — PhaseV, a clinical trial and development software startup, raised a $50 million Series A, CEO Raviv Pryluk tells Axios exclusively.
